From: The next generation of immunotherapy: keeping lung cancer in check
Ongoing trial name | Phase | Histology | Therapy | Setting | Endpoints (starting with primary) | Ref |
---|---|---|---|---|---|---|
KEYNOTE-021 | 1/2 | ALL | PEMBRO + PT-DC | Advanced, treatment-naïve NSCLC | PFS, ORR, OS, DOR, safety | [17] |
KEYNOTE-189 | 3 | ALL | PT-DC alone versus PT-DC + PEMBRO | Advanced, treatment-naïve NSCLC | PFS, ORR, OS, DOR, safety | [24] |
IMPower 130 | 3 | ALL | PT-DC + ATEZO | Advanced, treatment-naïve NSCLC | PFS, ORR, OS, DOR, safety | [26] |
IMPower 111 | 3 | SQ | Gemcitabine/PT + ATEZO | Advanced, treatment-naïve NSCLC | PFS, ORR, OS, DOR, safety | [29] |
IMPower 110 | 3 | NONSQ | Pemetrexed/PT + ATEZO | Advanced, treatment-naïve NSCLC | PFS, ORR, OS, DOR, safety | [28] |
IMPower 131 | 3 | SQ | Abraxane/PT + ATEZO | Advanced, treatment-naïve NSCLC | PFS, ORR, OS, DOR, safety | [27] |
IMPower 150 | 3 | NONSQ | PT-DC/ATEZO | Advanced, treatment-naïve NSCLC | PFS, ORR, OS, DOR, safety | [25] |
NEPTUNE | 3 | ALL | PT-DC alone versus durvalumab + tremelimumab | Advanced, treatment-naïve NSCLC | PFS, ORR, OS, DOR, safety | [30] |
MYSTIC | 3 | ALL | Durvalumab + tremelimumab | Advanced, treatment-naïve NSCLC | PFS, ORR, OS, DOR, safety | [31] |
PEARLS | 1b/2-3a | ALL | PEMBRO versus placebo | Adjuvant NSCLC | DFS, OS, lung cancer specific survival | [32] |
SAKK 16/14 | 2 | ALL | Durvalumab | Adjuvant NSCLC | Event-free survival at 1 and 5Â years, OS, ORR, safety | [33] |
NCT02259621 | 2 | ALL | NIVO | Neoadjuvant NSCLC | Safety | [34] |
Lung-MAP | 2/3 | SQ | Biomarker-driven combination with durvalumab, nivolumab, ipilimumab, and chemotherapy or targeted therapy | Advanced, pretreated SQ NSCLC | PFS, ORR, OS, DOR, safety | [16] |